YS Biopharma Co Ltd
NASDAQ:LSB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Honda India Power Products Ltd
NSE:HONDAPOWER
|
IN |
|
Care Property Invest NV
XBRU:CPINV
|
BE |
|
Shricon Industries Ltd
BSE:508961
|
IN |
|
GQG Partners Inc
ASX:GQG
|
US |
|
Vedavaag Systems Ltd
BSE:533056
|
IN |
|
Akeso Inc
HKEX:9926
|
CN |
|
Red Electrica Corporacion SA
LSE:0RI5
|
ES |
YS Biopharma Co Ltd
Total Receivables
YS Biopharma Co Ltd
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
YS Biopharma Co Ltd
NASDAQ:LSB
|
Total Receivables
¥501.8m
|
CAGR 3-Years
17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Total Receivables
¥5.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Total Receivables
¥1.7B
|
CAGR 3-Years
44%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Total Receivables
¥806.1m
|
CAGR 3-Years
38%
|
CAGR 5-Years
86%
|
CAGR 10-Years
N/A
|
|
|
|
Akeso Inc
HKEX:9926
|
Total Receivables
¥1B
|
CAGR 3-Years
38%
|
CAGR 5-Years
59%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Total Receivables
¥124.4m
|
CAGR 3-Years
6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
YS Biopharma Co Ltd
Glance View
YS Biopharma Co. Ltd. operates as a biopharmaceutical company, which is dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The company is headquartered in Beijing, Beijing. The firm's vaccine product YSJATM rabies vaccine has been commercialized. The firm also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
See Also
What is YS Biopharma Co Ltd's Total Receivables?
Total Receivables
501.8m
CNY
Based on the financial report for Mar 31, 2025, YS Biopharma Co Ltd's Total Receivables amounts to 501.8m CNY.
What is YS Biopharma Co Ltd's Total Receivables growth rate?
Total Receivables CAGR 3Y
17%
Over the last year, the Total Receivables growth was 12%. The average annual Total Receivables growth rates for YS Biopharma Co Ltd have been 17% over the past three years .
